West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services Price Performance
Shares of WST traded up $1.22 during trading hours on Friday, hitting $341.70. 214,019 shares of the company were exchanged, compared to its average volume of 427,400. The company has a market capitalization of $25.30 billion, a PE ratio of 37.92, a PEG ratio of 1.38 and a beta of 1.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.13 and a quick ratio of 2.41. The firm has a fifty day simple moving average of $308.62 and a 200-day simple moving average of $347.24. West Pharmaceutical Services has a one year low of $275.89 and a one year high of $475.35.
West Pharmaceutical Services (NYSE:WST - Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical instruments supplier reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.28. The business had revenue of $771.30 million during the quarter, compared to analyst estimates of $754.25 million. West Pharmaceutical Services had a return on equity of 29.08% and a net margin of 23.41%. The company's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $2.46 EPS. As a group, sell-side analysts predict that West Pharmaceutical Services will post 9.1 earnings per share for the current year.
Analysts Set New Price Targets
Separately, StockNews.com lowered West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research note on Thursday, April 28th.
Insider Transactions at West Pharmaceutical Services
In other news, insider Silji Abraham sold 5,374 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $343.93, for a total value of $1,848,279.82. Following the completion of the sale, the insider now owns 3,201 shares of the company's stock, valued at $1,100,919.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.60% of the stock is currently owned by insiders.